Healthcare / BiotechnologyNasdaqGM
$26.86
-0.17 (-0.63%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-97.1M · quality 78.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
47/100
C
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.3B
P/E
N/A
•EV/EBITDA
N/A
•ROE
145.5%
↑Gross Margin
88.7%
↑Debt/Equity
-1.22
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2016–2025 · 9 años de histórico normalizado
Revenue CAGR
+22.6%
FCF CAGR
—
FCF margin
-148.2%
FCF / Net income
1.06x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $109.8M · net income $-153.5M · FCF $-162.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | $109.8M | $109.8M | $90.4M | $82.7M | $64.4M | $48.0M | $11.8M | $18000.00 | $1.1M | $8.2M | $17.5M |
| Net Income | $-153.5M | $-153.5M | $-126.9M | $-102.2M | $-109.8M | $-110.8M | $-128.5M | $-105.1M | $-75.7M | $-20.0M | $-1.9M |
| EBITDA | $-135.7M | $-135.7M | $-110.3M | $-81.9M | $-97.8M | $-91.5M | $-126.3M | $-109.2M | $-76.8M | $-19.8M | $998000.00 |
| EPS | -3.19 | -3.19 | -2.96 | -3.55 | -4.79 | -4.96 | — | — | — | — | — |
| Gross Margin | 88.7% | 88.7% | 90.2% | 88.7% | 88.1% | 89.3% | 91.4% | 100.0% | -59.8% | 92.6% | 99.8% |
| Operating Margin | -113.7% | -113.7% | -107.1% | -79.2% | -122.8% | -192.1% | -1074.2% | -608211.1% | -6842.2% | -244.5% | 4.6% |
| Net Margin | -139.8% | -139.8% | -140.4% | -123.6% | -170.6% | -230.7% | -1088.9% | -584144.4% | -6707.2% | -245.2% | -11.1% |
| Balance Sheet | |||||||||||
| Debt/Equity | -1.22 | -1.22 | -14.02 | -1.52 | -1.11 | 0.00 | — | — | — | — | — |
| Current Ratio | 4.69 | 4.69 | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||
| Free Cash Flow | $-162.7M | $-162.7M | $-97.1M | $-76.6M | $-87.8M | $-85.6M | $-107.1M | $-71.3M | $-37.9M | $-9.8M | $3.5M |
| Returns | |||||||||||
| ROE | 145.5% | 145.5% | 1441.3% | 156.8% | 122.9% | -1317.2% | -133.3% | -58.3% | -84.0% | -29.2% | -11.9% |
| Growth & Yield | |||||||||||
| Revenue Growth | 21.4% | 21.4% | 9.3% | 28.5% | — | 307.2% | 65450.0% | -98.4% | -86.2% | -53.5% | — |
| EPS Growth | -7.8% | -7.8% | 16.6% | 25.9% | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+455.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.96 → -3.19
Residual
+455.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.